# Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

> **NCT04830124** · PHASE2 · TERMINATED · sponsor: **Mural Oncology, Inc** · enrollment: 173 (actual)

## Conditions studied

- Cutaneous Melanoma
- Mucosal Melanoma

## Interventions

- **DRUG:** Nemvaleukin Alfa Subcutaneous
- **DRUG:** Nemvaleukin Alfa Intravenous
- **DRUG:** Nemvaleukin Alfa Intravenous Less Frequent Dosing
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04830124
- **Lead sponsor:** Mural Oncology, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-27
- **Primary completion:** 2025-05-08
- **Final completion:** 2025-05-08
- **Target enrollment:** 173 (ACTUAL)
- **Why stopped:** Study terminated due to business and strategic decision.
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830124, "Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04830124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*